Cargando…
P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429314/ http://dx.doi.org/10.1097/01.HS9.0000969064.86312.d3 |
| _version_ | 1785090680809324544 |
|---|---|
| author | Hu, Lijuan Zhao, Wei-LI Wu, Wen Wei, Xudong MI, Ruihua Hu, Yu LI, Qiubai He, Wenjuan LI, Juan Dong, Yugang Wang, Hehua Zhang, Xuhan Zhang, Yu Xu, Zhongyuan Liu, Hui Cai, Zhen Sun, Jie Xu, Yajing Jiang, Zhiping Zhang, Cheng Chen, Guo Gong, Tiejun Tang, Qinghua Jing, Hongmei MA, Lan Gao, Sujun Liu, Qiqi Zhong, Zeyu Ren, Yongxin Chen, Jian Fan, Songhua Shi, Michael Su, Weiguo Huang, Xiaojun |
| author_facet | Hu, Lijuan Zhao, Wei-LI Wu, Wen Wei, Xudong MI, Ruihua Hu, Yu LI, Qiubai He, Wenjuan LI, Juan Dong, Yugang Wang, Hehua Zhang, Xuhan Zhang, Yu Xu, Zhongyuan Liu, Hui Cai, Zhen Sun, Jie Xu, Yajing Jiang, Zhiping Zhang, Cheng Chen, Guo Gong, Tiejun Tang, Qinghua Jing, Hongmei MA, Lan Gao, Sujun Liu, Qiqi Zhong, Zeyu Ren, Yongxin Chen, Jian Fan, Songhua Shi, Michael Su, Weiguo Huang, Xiaojun |
| author_sort | Hu, Lijuan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429314 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104293142023-08-17 P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS Hu, Lijuan Zhao, Wei-LI Wu, Wen Wei, Xudong MI, Ruihua Hu, Yu LI, Qiubai He, Wenjuan LI, Juan Dong, Yugang Wang, Hehua Zhang, Xuhan Zhang, Yu Xu, Zhongyuan Liu, Hui Cai, Zhen Sun, Jie Xu, Yajing Jiang, Zhiping Zhang, Cheng Chen, Guo Gong, Tiejun Tang, Qinghua Jing, Hongmei MA, Lan Gao, Sujun Liu, Qiqi Zhong, Zeyu Ren, Yongxin Chen, Jian Fan, Songhua Shi, Michael Su, Weiguo Huang, Xiaojun Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429314/ http://dx.doi.org/10.1097/01.HS9.0000969064.86312.d3 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Hu, Lijuan Zhao, Wei-LI Wu, Wen Wei, Xudong MI, Ruihua Hu, Yu LI, Qiubai He, Wenjuan LI, Juan Dong, Yugang Wang, Hehua Zhang, Xuhan Zhang, Yu Xu, Zhongyuan Liu, Hui Cai, Zhen Sun, Jie Xu, Yajing Jiang, Zhiping Zhang, Cheng Chen, Guo Gong, Tiejun Tang, Qinghua Jing, Hongmei MA, Lan Gao, Sujun Liu, Qiqi Zhong, Zeyu Ren, Yongxin Chen, Jian Fan, Songhua Shi, Michael Su, Weiguo Huang, Xiaojun P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title | P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title_full | P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title_fullStr | P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title_full_unstemmed | P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title_short | P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS |
| title_sort | p539: a phase 1 study of hmpl-306, a dual inhibitor of mutant isocitrate dehydrogenase (idh) 1 and 2, in pts with relapsed/refractory myeloid hematological malignancies harboring idh1 and/or 2 mutations |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429314/ http://dx.doi.org/10.1097/01.HS9.0000969064.86312.d3 |
| work_keys_str_mv | AT hulijuan p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT zhaoweili p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT wuwen p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT weixudong p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT miruihua p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT huyu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT liqiubai p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT hewenjuan p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT lijuan p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT dongyugang p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT wanghehua p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT zhangxuhan p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT zhangyu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT xuzhongyuan p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT liuhui p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT caizhen p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT sunjie p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT xuyajing p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT jiangzhiping p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT zhangcheng p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT chenguo p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT gongtiejun p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT tangqinghua p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT jinghongmei p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT malan p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT gaosujun p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT liuqiqi p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT zhongzeyu p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT renyongxin p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT chenjian p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT fansonghua p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT shimichael p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT suweiguo p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations AT huangxiaojun p539aphase1studyofhmpl306adualinhibitorofmutantisocitratedehydrogenaseidh1and2inptswithrelapsedrefractorymyeloidhematologicalmalignanciesharboringidh1andor2mutations |